Alvotech (ALVO) Q3 2026 Earnings Call Transcript

Alvotech (ALVO) reported Q3 2026 earnings, highlighting FDA approvals, strong revenue growth, and strategic partnerships. Revenue for the first 9 months was $323 million, with EBITDA of $78 million, up 15% year-over-year. The company expects Q4 to be its strongest quarter and anticipates performance to trend towards the lower end of its stated range.

Original reporting
Published Nov 12, 2026, 4:59 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 12, 2026, 5:13 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Alvotech (ALVO) Q3 2026 Earnings Call Transcript — source image
Decision brief

The 30-second read

$ALVOBearishMed
01

Why it matters

Earnings release provides fresh financial data and a lowered outlook, influencing investor sentiment and price.

02

Market read

First earnings disclosure for Q3 2026 with guidance cut, material for traders in biotech space.

03

What to watch

Recent FDA approvals and expanded manufacturing capacity may offset short‑term guidance concerns.

Relevance 7/10Novelty 7/10Timing: post‑earnings today

Background

Alvotech discussed Q3 results, manufacturing expansions, new US partnership with Lotus, and regulatory milestones.

Company-level read

Ticker impact

$ALVOBearishHigh confidence
Context

Q3 revenue $323M, EBITDA $78M (+15% YoY) and guidance lowered to the lower end of the previously stated range.

Expected impact

downside pressure as market prices in the lower guidance

Evidence & confidence

Guidance reduction is a material new fact that typically triggers a sell-off in biotech stocks.

Market effects

Biotech sector may see modest pullback as guidance cuts raise concerns on pipeline timing.

European biotech investors could reassess exposure to biosimilar developers.

Limited to niche biosimilar market; no broad macro impact.

Counterpoint

Despite guidance cut, strong pipeline and new US partnership could drive upside if execution succeeds.

Key entities

  • Alvotech

    Biopharma developing biosimilars, ticker ALVO.

  • Lotus Pharmaceutical

    Strategic partner for US commercialization of biosimilars.

Related articles

$ALVOMed

What Alvotech (ALVO) Said on Its Q3 Earnings Call

Alvotech (ALVO) reported Q3 revenue down 23% YoY, citing production delays and licensing timing. Adjusted EBITDA rose 15% to $78M. CEO maintained guidance despite delayed approvals. FDA approved manufacturing changes, doubling capacity. Cash fell to $61M due to working capital. Company expects Q4 cash-flow positivity and 2027 EBITDA improvement.

$ALVOHighAI 8/10

Alvotech (ALVO): Financial results for 9M

Alvotech (ALVO) furnished an SEC Form 6-K — earnings release. EXHIBIT 99.1 Alvotech Announces Financial Results for the Nine Months to September 30, 2026, with a Business Update REYKJAVIK, Iceland, Nov. 11, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO; ALVO-SDB) (“Alvotech” or the “Company”), a global biotechnology company specializing i